With 184.36 million shares changed hands, the volume of the stock remained heavier than its average volume of 10.86 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.2299 whereas the lowest price it dropped to was $3.5705. The 52-week range on SNGX shows that it touched its highest point at $5.40 and its lowest point at $1.09 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 2.09.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNGX was up-trending over the past week, with a rise of 103.28%, but this was up by 264.71% over a month. Three-month performance surged to 166.67% while six-month performance rose 107.53%. The stock gained 84.04% in the past year, while it has gained 55.49% so far this year. A look at the trailing 12-month EPS for SNGX yields -3.85 with Next year EPS estimates of -1.30. For the next quarter, that number is -0.65. This implies an EPS growth rate of 57.38% for this year and 50.00% for next year. EPS is expected to grow by 42.66% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 46.71%.
Float and Shares Shorts:
On 2025-07-31, short shares totaled 0.34 million, which was 1039.0 higher than short shares on 1751241600. In addition to Dr. Christopher J. Schaber Ph.D. as the firm’s Chairman of the Board of Directors, CEO & President, Mr. Jonathan L. Guarino CPA, CGMA serves as its Senior VP, CFO & Corporate Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, SNGX reported revenue of $0.0 and operating income of -$2763879.0. The EBITDA in the recently reported quarter was -$2755131.0 and diluted EPS was -$0.82.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With SNGX analysts setting a high price target of 35.0 and a low target of 10.0, the average target price over the next 12 months is 22.5. Based on these targets, SNGX could surge 605.65% to reach the target high and rise by 101.61% to reach the target low. Reaching the average price target will result in a growth of 353.63% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$7.1 being high and -$7.1 being low. For SNGX, this leads to a yearly average estimate of -$7.1. The surprise factor in the prior quarter was -$0.67. Based on analyst estimates, the high estimate for the next quarter is -$0.47 and the low estimate is -$0.47. The average estimate for the next quarter is thus -$0.47.
